RAXONE Chiesi Australia Pty Ltd
Product name
RAXONE
Sponsor
Accepted date
Mar-2026
Active ingredients
idebenone
Summary of proposed indication
RAXONE (idebenone) is indicated for the treatment of visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON), a rare, inherited genetic disease characterised by rapid, painless loss of central vision.
Application type
A (new medicine)
Publication date
Mar-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.